Aspirin Dosing for Essential Thrombocythemia

Increasing the frequency of low-dose aspirin dosing improved platelet inhibition.

Essential thrombocythemia (ET) is associated with an excess risk for arterial and venous thrombosis. Once-daily, low-dose aspirin (ASA) is often recommended as a means of reducing thrombosis risk, but efficacy is extrapolated from a randomized clinical trial involving patients with polycythemia vera (N Engl J Med 2004; 350:114). A recent meta-analysis reported uncertainty regarding the net effect of aspirin in ET, when weighing thrombosis risk reduction versus bleeding events (NEJM JW Oncol Hematol Aug 2017 and Ann Intern Med 2017; 167:170). Also, smaller studies have suggested that once-daily ASA dosing may result in incomplete platelet inhibition, due to renewal of COX-1 from enhanced platelet production.

To test whether increasing the fre…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Aspirin Dosing for Essential Thrombocythemia

Topics

Reviewing Author